Colistin: still a lifesaver for the 21st century?

References

• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–281.
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014;15:1351–1370.
   PubMed Web of Science ®Google Scholar
• Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16:161–168.
   PubMed Web of Science ®Google Scholar
• Skov RL, Monnet DL. Plasmid-mediated colistin resistance (mcr-1 gene): three months later, the story unfolds. Euro Surveill. 2016;21:30155. .
   PubMedGoogle Scholar
• Orwa JA, Govaerts R, Busson R, et al. Isolation and structural characterization of colistin components. J Antibiot (Tokyo). 2001;54:595–599.
   PubMed Web of Science ®Google Scholar
• Storm DR, Rosenthal KS, Swanson PE. Polymyxin and related peptide antibiotics. Annu Rev Biochem. 1977;46:723–763.
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Li J, Rayner CR, et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50:1953–1958.
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Landersdorfer CB, Zhang J, et al. Pharmacokinetics and pharmacodynamics of ‘old’ polymyxins: what is new? Diagn Microbiol Infect Dis. 2012;74:213–223.
   PubMed Web of Science ®Google Scholar
• Li J, Nation RL, Milne RW, et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2005;25:11–25.
   PubMed Web of Science ®Google Scholar
• Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005;3:238–250.
   PubMed Web of Science ®Google Scholar
• Mogi T, Kita K. Gramicidin S and polymyxins: the revival of cationic cyclic peptide antibiotics. Cell Mol Life Sci. 2009;66:3821–3826.
   PubMed Web of Science ®Google Scholar
• Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev. 2003;67:593–656.
   PubMed Web of Science ®Google Scholar
• Biswas S, Brunel JM, Dubus JC, et al. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther. 2012;10:917–934.
   PubMed Web of Science ®Google Scholar
• Deris ZZ, Akter J, Sivanesan S, et al. A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity. J Antibiot (Tokyo). 2014;67:147–151.
   PubMed Web of Science ®Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0; 2016 [cited 2016 Jun 3]. Available from: http://www.eucast.org
   Google Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing. 26th ed. CLSI supplement M100S. Wayne (PA): Clinical and Laboratory Standards Institute; 2016.
   Google Scholar
• Dafopoulou K, Zarkotou O, Dimitroulia E, et al. Comparative evaluation of colistin susceptibility testing methods among carbapenem-nonsusceptible Klebsiella pneumoniae and Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother. 2015;59:4625–4630.
   PubMed Web of Science ®Google Scholar
• Hindler JA, Humphries RM. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli. J Clin Microbiol. 2013;51:1678–1684.
   PubMed Web of Science ®Google Scholar
• Albur M, Noel A, Bowker K, et al. Colistin susceptibility testing: time for a review. J Antimicrob Chemother. 2014;69:1432–1434.
   PubMed Web of Science ®Google Scholar
• van der Heijden IM, Levin AS, De Pedri EH, et al. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins. Ann Clin Microbiol Antimicrob. 2007;6:8.
   PubMedGoogle Scholar
• Sader HS, Farrell DJ, Castanheira M, et al. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12). J Antimicrob Chemother. 2014;69:2713–2722.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2014. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2015. DOI:10.2900/23549 Available from: http://ecdc.europa.eu/en/publications/
   Google Scholar
• Zhanel GG, Adam HJ. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007–11 study. J Antimicrob Chemother. 2013;68(Suppl 1):i7–i22.
   PubMed Web of Science ®Google Scholar
• Bradford PA, Kazmierczak KM, Biedenbach DJ, et al. Correlation of β-lactamase production and colistin resistance among Enterobacteriaceae isolates from a global surveillance program. Antimicrob Agents Chemother. 2016;60:1385–1392.
   Web of Science ®Google Scholar
• Giani T, Pini B, Arena F, et al. Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey. Euro Surveill. 2013;18(22):pii=20489.
   PubMedGoogle Scholar
• Oteo J, Ortega A, Bartolomé R, et al. Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem. Antimicrob Agents Chemother. 2015;59:3406–3412.
   PubMed Web of Science ®Google Scholar
• Spyropoulou A, Papadimitriou-Olivgeris M, Bartzavali C, et al. A ten-year surveillance study of carbapenemase-producing Klebsiella pneumoniae in a tertiary care Greek university hospital: predominance of KPC- over VIM- or NDM-producing isolates. J Med Microbiol. 2016;65:240–246.
   PubMed Web of Science ®Google Scholar
• Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother. 2009;53:3430–3436.
   PubMed Web of Science ®Google Scholar
• Jayol A, Nordmann P, Brink A, et al. Heteroresistance to colistin in Klebsiella pneumoniae associated with alterations in the PhoPQ regulatory system. Antimicrob Agents Chemother. 2015;59:2780–2784.
   PubMed Web of Science ®Google Scholar
• Choi MJ, Park YK, Peck KR, et al. Mutant prevention concentrations of colistin used in combination with other antimicrobial agents against Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa clinical isolates. Int J Antimicrob Agents. 2014;44:469–476.
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Tsuji BT, Bulitta JB, et al. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2011;55:5685–5695.
   PubMed Web of Science ®Google Scholar
• Zusman O, Avni T, Leibovici L, et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013;57:5104–5111.
   PubMed Web of Science ®Google Scholar
• Souli M, Rekatsina PD, Chryssouli Z, et al. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-β-lactamase-producing Klebsiella pneumoniae Isolates? Antimicrob Agents Chemother. 2009;53:2133–2135.
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Hao B, Shields RK, et al. Doripenem, gentamicin and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes. Antimicrob Agents Chemother. 2014;58:3521–3525.
   PubMed Web of Science ®Google Scholar
• Deris ZZ, Yu HH, Davis K, et al. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2012;56:5103–5112.
   PubMed Web of Science ®Google Scholar
• Betts JW, Phee LM, Hornsey M, et al. In vitro and in vivo activity of tigecycline/colistin combination therapies against carbapenem resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2014;58:3541–3546.
   PubMed Web of Science ®Google Scholar
• Albur M, Noel A, Bowker K, et al. Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2012;56:3441–3443.
   PubMed Web of Science ®Google Scholar
• Souli M, Galani I, Boukovalas S, et al. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development. Antimicrob Agents Chemother. 2011;55:2395–2397.
   PubMed Web of Science ®Google Scholar
• Albur M, Noel A, Bowker K, et al. The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments. Int J Antimicrob Agents. 2015;46:560–567.
   PubMed Web of Science ®Google Scholar
• Abdul Rahim N, Cheah SE, Johnson MD, et al. Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two ‘old’ antibiotics-polymyxin B and chloramphenicol. J Antimicrob Chemother. 2015;70:2589–2597.
   PubMed Web of Science ®Google Scholar
• Tängdén T, Hickman RA, Forsberg P, et al. Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother. 2014;58:1757–1762.
   PubMed Web of Science ®Google Scholar
• Ni W, Shao X, Di X, et al. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: A systematic review and meta-analysis. Int J Antimicrob Agents. 2015;45:8–18.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Bergen PJ, Bulitta JB, et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2013;57:3738–3745.
   PubMed Web of Science ®Google Scholar
• Galani I, Orlandou K, Moraitou H, et al. Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2014;43:370–374.
   PubMed Web of Science ®Google Scholar
• Phee LM, Betts JW, Bharathan B, et al. Colistin and fusidic acid, a novel potent synergistic combination for treatment of multidrug-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2015;59:4544–4550.
   PubMed Web of Science ®Google Scholar
• Martis N, Leroy S, Blanc V, et al. Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections. A narrative review for the clinician. J Infect. 2014;69:1–12.
   PubMed Web of Science ®Google Scholar
• Zeidler U, Bougnoux ME, Lupan A, et al. Synergy of the antibiotic colistin with echinocandin antifungals in Candida species. J Antimicrob Chemother. 2013;68:1285–1296.
   PubMed Web of Science ®Google Scholar
• Schemuth H, Dittmer S, Lackner M, et al. In vitro activity of colistin as single agent and in combination with antifungals against filamentous fungi occurring in patients with cystic fibrosis. Mycoses. 2013;56:297–303.
   PubMed Web of Science ®Google Scholar
• Nation RL, Velkov T, Li J. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis. 2014;59(1):88–94.
   PubMed Web of Science ®Google Scholar
• Cheah SE, Li J, Tsuji BT, et al. Colistin and polymyxin B dosage regimens against Acinetobacter baumannii: differences in activity and the emergence of resistance. Antimicrob Agents Chemother. 2016;60:3921–33.
   Web of Science ®Google Scholar
• Jansson B, Karvanen M, Cars O, et al. Quantitative analysis of colistin A and colistin B in plasma and culture medium using a simple precipitation step followed by LC/MS/MS. J Pharm Biomed Anal. 2009;49(3):760–767.
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–1596.
   PubMed Web of Science ®Google Scholar
• Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother. 2012;56:4241–4249.
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Friberg LE, Pontikis K, et al. Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate (CMS) in critically ill patients. Antimicrob Agents Chemother. 2015;59:7240–7248.
   PubMed Web of Science ®Google Scholar
• Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284–3294.
   PubMed Web of Science ®Google Scholar
• Nation RL, Garonzik SM, Li J, et al. Updated US and European dose recommendations for intravenous colistin: how do they perform? Clin Infect Dis. 2016;62(5):552–558.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency completes review of polymyxin-based medicine: recommendations issued for safe use in patients with serious infections resistant to standard antibiotics. Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/Referrals_document/Polymyxin_31/WC500176332.pdf.
   Google Scholar
• Karvanen M, Plachouras D, Friberg LE, et al. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother. 2013;57:668–671.
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Friberg LE, Galani L, et al. Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous hemodiafiltration. Int J Antimicrob Agents. 2016; doi:10.1016/j.ijantimicag.2016.06.008. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Honoré PM, Jacobs R, Joannes-Boyau O, et al. Continuous renal replacement therapy-related strategies to avoid colistin toxicity: a clinically orientated review. Blood Purif. 2014;37:291–295.
   PubMed Web of Science ®Google Scholar
• Koomanachai P, Landersdorfer CB, Chen G, et al. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother. 2014;58:440–446.
   PubMed Web of Science ®Google Scholar
• Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest. 2010;138:1333–1339.
   PubMed Web of Science ®Google Scholar
• Athanassa ZE, Markantonis SL, Fousteri MZ, et al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med. 2012;38:1779–1786.
   PubMed Web of Science ®Google Scholar
• Boisson M, Jacobs M, Grégoire N, et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother. 2014;58:7331–7339.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35:194–199.
   PubMed Web of Science ®Google Scholar
• Vicari G, Bauer SR, Neuner EA, et al. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant Gram-negative bacteremia. Clin Infect Dis. 2013;56:398–404.
   PubMed Web of Science ®Google Scholar
• Gibson GA, Bauer SR, Neuner EA, et al. Influence of colistin dose on global cure in patients with bacteremia due to carbapenem-resistant Gram-negative bacilli. Antimicrob Agents Chemother. 2015;60:431–436.
   PubMed Web of Science ®Google Scholar
• Dalfino L, Puntillo F, Ondok MJ, et al. Colistin-associated acute kidney injury in severely ill patients: a step toward a better renal care? A prospective cohort study. Clin Infect Dis. 2015;61:1771–1777.
   PubMed Web of Science ®Google Scholar
• Tzouvelekis LS, Markogiannakis A, Piperaki E, et al. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2014;20:862–872.
   PubMed Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322–2328.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70:2133–2143.
   PubMed Web of Science ®Google Scholar
• Bergen PJ, Bulman ZP, Landersdorfer CB, et al. Optimizing polymyxin combinations against resistant Gram-negative bacteria. Infect Dis Ther. 2015;4:391–415.
   PubMedGoogle Scholar
• Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2003;37:e154–e160.
   PubMed Web of Science ®Google Scholar
• López-Cortés LE, Cisneros JM, Fernández-Cuenca F, et al. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother. 2014;69:3119–3126.
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57:349–358.
   PubMed Web of Science ®Google Scholar
• Liu Q, Li W, Feng Y, et al. Efficacy and safety of polymyxins for the treatment of Acinetobacter baumannii infection: a systematic review and meta-analysis. PLoS One. 2014;9:e98091.
   Google Scholar
• Petrosillo N, Giannella M, Antonelli M, et al. Clinical experience of colistin glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Antimicrob Agents Chemother. 2014;58:851–858.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Amaya-Villar R, Gutiérrez-Pizarraya A, et al. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemotherapy. 2013;59:225–231.
   PubMed Web of Science ®Google Scholar
• Dickstein Y, Leibovici L, Yahav D, et al. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. BMJ Open. 2016;6:e009956.
   PubMed Web of Science ®Google Scholar
• Palmer LB. Ventilator-associated infection: the role for inhaled antibiotics. Curr Opin Pulm Med. 2015;21:239–249.
   PubMed Web of Science ®Google Scholar
• Rouby J, Bouhemad B, Monsel A, et al. Aerosolized antibiotics for ventilator-associated pneumonia: lessons from experimental studies. Anesthesiology. 2012;117:1364–1380.
   PubMed Web of Science ®Google Scholar
• Valachis A, Samonis G, Kofteridis DP. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit Care Med. 2015;43(3):527–533.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, De Pascale G, Trecarichi EM, et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator associated pneumonia caused by colistin only susceptible gram-negative bacteria. Chest. 2013;144:1768–1775.
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Galani L, Baziaka F, et al. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. Int J Antimicrob Agents. 2013;41(6):499–508.
   PubMed Web of Science ®Google Scholar
• Bargiacchi O, De Rosa FG. Intrathecal or intraventricular colistin: a review. Infez Med. 2016;24:3–11.
   PubMedGoogle Scholar
• Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents. 2007;29:9–25.
   PubMed Web of Science ®Google Scholar
• Kelesidis T, Falagas ME. The safety of polymyxin antibiotics. Expert Opin Drug Saf. 2015;14:1687–1701.
   PubMed Web of Science ®Google Scholar
• Ortwine JK, Sutton JD, Kaye KS, et al. Strategies for the safe use of colistin. Expert Rev Anti Infect Ther. 2015;13:1237–1247.
   PubMed Web of Science ®Google Scholar
• Sirijatuphat R, Limmahakhun S, Sirivatanauksorn V, et al. Preliminary clinical study of the effect of ascorbic acid on colistin-associated nephrotoxicity. Antimicrob Agents Chemother. 2015;59:3224–3232.
   PubMed Web of Science ®Google Scholar
• Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol. 2014;5:643. .
   PubMed Web of Science ®Google Scholar
• Velkov T, Roberts KD, Nation RL, et al. Pharmacology of polymyxins: new insights into an ‘old’ class of antibiotics. Future Microbiol. 2013;8:711–724.
   PubMed Web of Science ®Google Scholar
• Wright MS, Suzuki Y, Jones MB, et al. Genomic and transcriptomic analyses of colistin-resistant clinical isolates of Klebsiella pneumoniae reveal multiple pathways of resistance. Antimicrob Agents Chemother. 2015;59:536–543.
   PubMed Web of Science ®Google Scholar
• Jayol A, Nordmann P, Desroches M, et al. Acquisition of broad-spectrum cephalosporin resistance leading to colistin resistance in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2016;60:3199–3201.
   PubMed Web of Science ®Google Scholar
• Zowawi HM, Forde BM, Alfaresi M, et al. Stepwise evolution of pandrug-resistance in Klebsiella pneumoniae. Sci Rep. 2015;5:15082.
   PubMed Web of Science ®Google Scholar
• Elnahriry SS, Khalifa HO, Soliman AM, et al. Emergence of plasmid-mediated colistin resistance gene mcr-1 in a clinical Escherichia coli isolate from Egypt. Antimicrob Agents Chemother. 2016;60:3249–3250.
   PubMed Web of Science ®Google Scholar
• Cannatelli A, Giani T, Antonelli A, et al. First detection of the mcr-1 colistin resistance gene in Escherichia coli in Italy. Antimicrob Agents Chemother. 2016;60:3257–3258.
   PubMed Web of Science ®Google Scholar
• Prim N, Rivera A, Rodriguez-Navarro J, et al. Detection of mcr-1 colistin resistance gene in polyclonal Escherichia coli isolates in Barcelona, Spain, 2012 to 2015. Euro Surveill. 2016;21:30183.
   Google Scholar
• Fernandes MR, Moura Q, Sartori L, et al. Silent dissemination of colistin-resistant Escherichia coli in South America could contribute to the global spread of the mcr-1 gene. Euro Surveill. 2016;21:30214.
   Google Scholar
• Nordmann P, Poirel L. Plasmid-mediated colistin resistance: an additional antibiotic resistance menace. Clin Microbiol Infect. 2016;22:398–400.
   PubMed Web of Science ®Google Scholar
• Li A, Yang Y, Miao M, et al. Complete sequences of mcr-1-harboring plasmids from extended spectrum β-lactamase (ESBL) – and carbapenemase-producing Enterobacteriaceae (CPE). Antimicrob Agents Chemother. 2016;60:4351–4354.
   Web of Science ®Google Scholar
• McGann P, Snesrud E, Maybank R, et al. Escherichia coli harboring mcr-1 and blaCTX-M on a novel IncF plasmid: first report of mcr-1 in the USA. Antimicrob Agents Chemother. 2016;60:4420–4421.
   Web of Science ®Google Scholar
• Petrillo M, Angers-Loustau A, Kreysa J. Possible genetic events producing colistin resistance gene mcr-1. Lancet Infect Dis. 2016;16:280.
   PubMed Web of Science ®Google Scholar